Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1281032

registered interest
date	27/01/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Vaccine Manufacturing and Innovation Centre: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, pursuant to the Answer of 26 January 2021 to Question 141474, how many additional vaccine doses per month the expanded Vaccine Manufacturing Innovation Centre facility can produce as a result of the investment outlined in that Answer; and of which types of vaccine.
tabling member constituency	Cardiff South and Penarth
tabling member printed	Stephen Doughty
uin	144691
answer	answer is ministerial correction date of answer 01/02/2021 answer text <p>When fully operationally in 2022, the Vaccines Manufacturing and Innovation Centre (VMIC) will have several Good Manufacturing Process suites that will be able to accommodate a range of production scale capabilities. For pandemic response, the VMIC will be able to make up to 70 million doses of a vaccine within a 6-month timeframe. This is a significant increase to the VMIC’s originally anticipated capacity.</p><p> </p><p>The VMIC has been designed to be a flexible manufacturing facility and will be able to manufacture a range of vaccine types, such as messenger RNA, viral vector, or protein sub-unit.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 01/02/2021 16:13:48 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4264 label Biography information for Stephen Doughty

1280122

registered interest
date	25/01/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Vaccine Manufacturing and Innovation Centre
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, when the expansion of the VMIC facility is planned to be completed.
tabling member constituency	Cardiff South and Penarth
tabling member printed	Stephen Doughty
uin	142941
answer	answer is ministerial correction date of answer 28/01/2021 answer text <p>The Vaccines Manufacturing and Innovation Centre (VMIC) should be partially open in summer 2021, with the facility fully operational in 2022. The VMIC is working towards having fill-finish capability at the end of 2021. The objective remains to accelerate the readiness of the VMIC by a year and it is on track to achieve this, but it is also important to remember this is a complex project being delivered in unprecedented times.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 28/01/2021 17:21:34 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4264 label Biography information for Stephen Doughty

1280124

registered interest
date	25/01/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, whether the (a) design, (b) bio-engineering and (c) manufacture of vaccines capable of responding to the 501 and 484 variants of covid-19 has commenced.
tabling member constituency	Cardiff South and Penarth
tabling member printed	Stephen Doughty
uin	142942
answer	answer is ministerial correction date of answer 28/01/2021 answer text <p>The Government is currently undertaking its own laboratory work as a priority to better understand the impact of the new Covid-19 variants on the vaccines currently in deployment, in particular the risk of vaccine resistance. We maintain close contact with vaccine developers to understand their own studies as to the efficacy of their vaccines on variants and the impact on current supply chain arrangements for their manufacture.</p><p> </p><p>We continue to take a portfolio-based approach that monitors the landscape of Covid-19 vaccine development and we remain confident that the three vaccines (Pfizer/BioNTech, Oxford University/AstraZeneca, and Moderna) that we have purchased, which have been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA), will continue to be effective against the virus.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 28/01/2021 17:19:44 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4264 label Biography information for Stephen Doughty

1280125

registered interest
date	25/01/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, when vaccines capable of responding to the 501 and 484 variants of covid-19 will be available for use in the general population.
tabling member constituency	Cardiff South and Penarth
tabling member printed	Stephen Doughty
uin	142943
answer	answer is ministerial correction date of answer 28/01/2021 answer text <p>The Government is currently undertaking its own laboratory work as a priority to better understand the impact of the new Covid-19 variants on the vaccines currently in deployment, in particular the risk of vaccine resistance. We maintain close contact with vaccine developers to understand their own studies as to the efficacy of their vaccines on variants and the impact on current supply chain arrangements for their manufacture.</p><p> </p><p>We continue to take a portfolio-based approach that monitors the landscape of Covid-19 vaccine development and we remain confident that the three vaccines (Pfizer/BioNTech, Oxford University/AstraZeneca, and Moderna) that we have purchased, which have been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA), will continue to be effective against the virus.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 28/01/2021 17:17:49 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4264 label Biography information for Stephen Doughty

1279579

registered interest
date	22/01/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, how many doses of the (a) Pfizer-BioNTech and (b) Oxford-AstraZeneca vaccine are physically present in the UK and being held in storage, yet to be deployed or prepared for delivery.
tabling member constituency	Cardiff South and Penarth
tabling member printed	Stephen Doughty
uin	141990
answer	answer is ministerial correction date of answer 27/01/2021 answer text <p>The Government has procured 40 million doses of the Pfizer/BioNTech and 100 million doses of the Oxford University/AstraZeneca vaccines.</p><p> </p><p>The UK was the first country in the world to start a vaccination programme using these vaccines. As of 26 January 2021, over 6.85 million people across the UK have been vaccinated with the first dose of the vaccine. We continue to work to meet our target of vaccinating all four priority groups by 15 February.</p><p> </p><p>Vaccines are a precious resource in very high demand across the world; therefore, for security reasons it is not possible to provide detail about the size of our supplies and exact detail about deliveries.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 27/01/2021 17:19:30 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4264 label Biography information for Stephen Doughty

1279593

registered interest
date	22/01/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, how many UK based manufacturing facilities are capable of re-engineering and manufacturing (a) mRNA, (b) viral vector, (c) whole virus and (d) protein subunit vaccines to address emerging variants of the covid-19 virus.
tabling member constituency	Cardiff South and Penarth
tabling member printed	Stephen Doughty
uin	141992
answer	answer is ministerial correction date of answer 27/01/2021 answer text <p>The Government has made several strategic investments in UK vaccine manufacturing capabilities to increase its capacity, ensuring we are able to manufacture across different vaccine technologies and embed resilience. This includes:</p><p> </p><ul><li>The acceleration and expansion of flexible vaccine manufacturing capabilities at the UK’s first Vaccine Manufacturing and Innovation Centre (VMIC) in Harwell.</li><li>Collaborating with the Cell and Gene Therapy Catapult to fund a state-of-the-art Manufacturing Innovation Centre in Braintree.</li><li>Expansion of the Valneva factory in Livingston, Scotland, which is capable of whole virus manufacture.</li></ul><p> </p><p>Both the VMIC and Braintree sites are flexible to vaccine types, including messenger RNA (mRNA), viral vector, and protein sub-unit. These sites could have a role in providing capability to manufacture vaccines to address the emerging variants of the COVID-19 virus.</p><p> </p><p>The Government has also invested through UK Research and Innovation (UKRI) to support the creation of a new Centre of Excellence in mRNA vaccine manufacture at the Centre for Process Innovation (CPI), with equipment that can manufacture mRNA for vaccines. This funding has upgraded CPI’s National Biologics Manufacturing Centre at Darlington to obtain good manufacturing practice certification for the manufacture of RNA products including mRNA for clinical trials. A key advantage of RNA vaccines is how quickly they can be developed compared with other platforms.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 27/01/2021 17:18:03 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4264 label Biography information for Stephen Doughty

1279278

registered interest
date	21/01/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, pursuant to the Answers of 19 January 2021 to Questions 137942 and 137941, if he will provide a breakdown of the £300 million invested in securing and scaling up UK manufacturing capacity by (a) type of capacity, (b) geographical location and (c) the date that investment was delivered.
tabling member constituency	Cardiff South and Penarth
tabling member printed	Stephen Doughty
uin	141474
answer	answer is ministerial correction date of answer 26/01/2021 answer text <p>The Government invested over £300 million in 2020 to secure and scale-up the UK’s manufacturing capabilities to respond to this pandemic, including:</p><p>- £127 million towards the Cell and Gene Therapy Catapult Braintree in Essex;</p><p>- £93 million to accelerate the completion and expanded role of the Vaccine Manufacturing Innovation Centre in Oxfordshire;</p><p>- £4.7 million for skills training through the Advanced Therapies Skills Training Network, which will be delivered through both virtual and physical centres;</p><p>- £8.75 million for the set-up of the rapid deployment facility at Oxford Biomedica in Oxfordshire; and</p><p>- £65.5 million for the manufacture of the University of Oxford / AstraZeneca vaccine.</p><p> </p><p>In addition to the above, we have also funded the fill and finish of vaccines through a contract with Wockhardt in Wrexham, North Wales, as well as the expansion of the Valneva factory in Livingston, Scotland. However, we are not able to give further details on these two developments owing to commercial confidentiality.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 26/01/2021 16:15:42 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4264 label Biography information for Stephen Doughty

1279279

registered interest
date	21/01/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what steps he is taking to secure UK covid-19 vaccine manufacturing capacity and protect those manufacturing establishments from flood, fire, malfunction and other security threats.
tabling member constituency	Cardiff South and Penarth
tabling member printed	Stephen Doughty
uin	141475
answer	answer is ministerial correction date of answer 26/01/2021 answer text <p>The Government takes security extremely seriously and is ensuring all necessary steps are taken.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 26/01/2021 16:08:01 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4264 label Biography information for Stephen Doughty

1277461

registered interest
date	18/01/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, whether the decision by Pfizer to make changes to manufacturing processes of its covid-19 vaccine to boost production will affect the distribution of that vaccine to the UK from late January to early February 2021.
tabling member constituency	Cardiff South and Penarth
tabling member printed	Stephen Doughty
uin	139002
answer	answer is ministerial correction date of answer 21/01/2021 answer text <p>Vaccines are a precious resource and are in very high demand across the world; therefore, for security reasons it is not possible to provide detail about the size of our supplies or give exact detail about future deliveries.</p><p> </p><p>We have been monitoring the requirements across the supply chain from supplier through to patients for some time. All vaccine candidates’ supply and onward deployment have clear supply chain plans across the value chain, including materials, manufacturing, transportation, storage, and distribution.</p><p> </p><p>As of 18 January 2021, over 4.6 million people in the UK had been vaccinated with the first dose of the vaccine. We are in the process of understanding the implications of Pfizer’s announcement on 15 January regarding upgrades to its manufacturing capacity. We continue to work to meet our target of vaccinating all four priority groups, as advised by the Joint Committee on Vaccination and Immunisation, by the middle of February.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 21/01/2021 16:21:01 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4264 label Biography information for Stephen Doughty

1276760

registered interest
date	14/01/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Vaccination: Manufacturing Industries
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, how many vaccine manufacturing facilities (a) for the production of raw materials, active ingredients, coupling and formulation and (b) for fill and finish there are in the UK; and how many of those facilities are being used for covid-19 vaccine production.
tabling member constituency	Cardiff South and Penarth
tabling member printed	Stephen Doughty
uin	137941
answer	answer is ministerial correction date of answer 19/01/2021 answer text <p>We have been monitoring the requirements across the supply chain from supplier through to patients for some time. All vaccine candidates’ supply and onward deployment have clear supply chain plans across the value chain, including materials, manufacturing, transportation, storage, and distribution. <br> <br> Three of the UK's seven COVID-19 vaccines are being manufactured in the UK. The Government has worked closely with the manufacturers to ensure that we have sufficient capacity secured.</p><p>The Government has also invested over £300 million in securing and scaling up the UK’s manufacturing capabilities to be able to respond to this pandemic.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi grouped question UIN 137942 question first answered 19/01/2021 17:29:58 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4264 label Biography information for Stephen Doughty